{"id":"tacrolimus-modified-release","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting calcineurin, tacrolimus modified-release suppresses the immune system's response, which can help prevent organ rejection in transplant patients. This is achieved by blocking the transcription of interleukin-2, a key cytokine involved in T-cell activation.","oneSentence":"Tacrolimus modified-release works by inhibiting calcineurin, which is involved in the activation of T-lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:14.563Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney transplant patients"}]},"trialDetails":[{"nctId":"NCT06751992","phase":"PHASE4","title":"Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-17","conditions":"Kidney Transplant Recipients, Old Age","enrollment":92},{"nctId":"NCT07364123","phase":"NA","title":"Kidney Transplant Immunosuppressive Therapy Adherence Trial (KITE)","status":"NOT_YET_RECRUITING","sponsor":"University of Gaziantep","startDate":"2026-01-05","conditions":"Kidney Transplantation, Medication Non-Adherence, Immunosuppressive Therapy","enrollment":60},{"nctId":"NCT01294020","phase":"PHASE2","title":"Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-05-25","conditions":"Intestine Transplantation, Kidney Transplantation, Lung Transplantation","enrollment":81},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT02118896","phase":"PHASE3","title":"Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2003-02-24","conditions":"Heart Transplantation, Liver Transplantation, Kidney Transplantation","enrollment":850},{"nctId":"NCT01011205","phase":"PHASE3","title":"Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09-30","conditions":"Liver Transplantation","enrollment":893},{"nctId":"NCT01304836","phase":"PHASE4","title":"A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-01-22","conditions":"Kidney Transplantation","enrollment":1166},{"nctId":"NCT02268201","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule","status":"TERMINATED","sponsor":"Astellas Pharma China, Inc.","startDate":"2013-07-23","conditions":"Kidney Transplant Recipients","enrollment":17},{"nctId":"NCT01882322","phase":"PHASE4","title":"A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2013-01-30","conditions":"de Novo Liver Transplant Subjects","enrollment":36},{"nctId":"NCT03623217","phase":"","title":"Quality of Life Questionnaire Validation for Patients With Changed Tacrolimus Dosing After Kidney Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2015-02-24","conditions":"Kidney Transplantation","enrollment":56},{"nctId":"NCT06591884","phase":"PHASE1, PHASE2","title":"Evaluation of the Efficacy of 0.08% Tacrolimus Nanoencapsulated Aqueous Solution Spray Vs. 0.1% Free Tacrolimus Commercial Ointment in the Treatment of Oral Lichen Planus","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-09-03","conditions":"Oral Erosive Lichen Planus","enrollment":46},{"nctId":"NCT04711291","phase":"NA","title":"Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes","status":"WITHDRAWN","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-06-01","conditions":"Medication Adherence, Renal Transplant","enrollment":""},{"nctId":"NCT02341274","phase":"PHASE1","title":"Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers","status":"COMPLETED","sponsor":"Indiana University","startDate":"2016-11-11","conditions":"Bioequivalence","enrollment":24},{"nctId":"NCT00579527","phase":"PHASE1, PHASE2","title":"Phase I/II Thymus Transplantation With Immunosuppression #950","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2005-12-19","conditions":"DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly","enrollment":14},{"nctId":"NCT04763096","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of the ADVAGRAF®","status":"COMPLETED","sponsor":"Linical Korea","startDate":"2016-11","conditions":"Evidence of Liver Transplantation","enrollment":101},{"nctId":"NCT04761731","phase":"PHASE4","title":"To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients","status":"COMPLETED","sponsor":"Linical Korea","startDate":"2015-07","conditions":"Liver Transplantation","enrollment":31},{"nctId":"NCT03751332","phase":"PHASE4","title":"The Vienna Prograf and Endothelial Progenitor Cell Extension Study","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2008-03","conditions":"Immunosuppression, Renal Failure","enrollment":87},{"nctId":"NCT03423225","phase":"PHASE4","title":"To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients","status":"COMPLETED","sponsor":"Kim, Seoung-Hoon","startDate":"2016-03-22","conditions":"Liver Transplantation","enrollment":31},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT01339468","phase":"PHASE4","title":"A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-04-27","conditions":"Liver Transplantation","enrollment":100},{"nctId":"NCT02545972","phase":"PHASE4","title":"Once-a-day Tacrolimus Conversion Study: The OneTAC Trial","status":"UNKNOWN","sponsor":"Newark Beth Israel Medical Center","startDate":"2016-02","conditions":"Heart Failure","enrollment":100},{"nctId":"NCT00459719","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-03","conditions":"Liver Transplantation","enrollment":42},{"nctId":"NCT00619398","phase":"PHASE3","title":"A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-01","conditions":"Liver Transplantation","enrollment":172},{"nctId":"NCT00481819","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":240},{"nctId":"NCT00166712","phase":"PHASE4","title":"A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2005-04","conditions":"Kidney Transplant Failure and Rejection","enrollment":40},{"nctId":"NCT00817206","phase":"PHASE3","title":"Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-12","conditions":"Renal Failure","enrollment":326},{"nctId":"NCT00496483","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-07","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT00772148","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-10","conditions":"Liver Failure","enrollment":58},{"nctId":"NCT01332201","phase":"PHASE2","title":"Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-07","conditions":"Heart Transplantation, Lung Transplantation, Pancreas (Including SPK) Transplantation","enrollment":17},{"nctId":"NCT00765661","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-09","conditions":"Kidney Failure, Renal Failure","enrollment":63},{"nctId":"NCT02432053","phase":"PHASE4","title":"A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-03","conditions":"Kidney Transplantation, Liver Transplantation","enrollment":92},{"nctId":"NCT02311010","phase":"PHASE4","title":"Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism","status":"UNKNOWN","sponsor":"Université Catholique de Louvain","startDate":"2011-01","conditions":"Kidney Diseases","enrollment":150},{"nctId":"NCT01742676","phase":"PHASE4","title":"A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2011-04","conditions":"Renal Transplantation, Kidney Transplantation, Stable Renal Recipients","enrollment":100},{"nctId":"NCT01435291","phase":"PHASE4","title":"AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2011-10","conditions":"Renal Transplantation","enrollment":45},{"nctId":"NCT00865137","phase":"PHASE3","title":"An Open Study Assessing Bioavailability of a Modified Formulation of Tacrolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-09","conditions":"Kidney Transplantation","enrollment":27},{"nctId":"NCT00481481","phase":"PHASE3","title":"Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-04","conditions":"Transplantation","enrollment":346},{"nctId":"NCT00384202","phase":"PHASE3","title":"A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-10","conditions":"Transplantation","enrollment":112},{"nctId":"NCT00189839","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-08","conditions":"Kidney Transplantation","enrollment":699},{"nctId":"NCT00189826","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-08","conditions":"Liver Transplantation","enrollment":475},{"nctId":"NCT00384137","phase":"PHASE3","title":"A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-10","conditions":"Transplantation","enrollment":128},{"nctId":"NCT01049633","phase":"","title":"B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00064701","phase":"PHASE3","title":"Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-06","conditions":"Kidney Transplantation","enrollment":668},{"nctId":"NCT00282256","phase":"PHASE2","title":"A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-01","conditions":"Liver Transplantation","enrollment":19},{"nctId":"NCT00282243","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-02","conditions":"Liver Transplantation","enrollment":70},{"nctId":"NCT00282568","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-08","conditions":"Kidney Transplantation","enrollment":70},{"nctId":"NCT01839929","phase":"PHASE4","title":"A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2010-09","conditions":"Kidney Transplantation","enrollment":138},{"nctId":"NCT00909571","phase":"PHASE3","title":"Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04","conditions":"Liver Transplantation","enrollment":10},{"nctId":"NCT00719745","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-02","conditions":"Liver Transplantation","enrollment":74},{"nctId":"NCT00720265","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-02","conditions":"Kidney Transplantation","enrollment":135}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"APLASIA PURE RED CELL"},{"count":1,"reaction":"ESCHERICHIA URINARY TRACT INFECTION"},{"count":1,"reaction":"HERPES ZOSTER"},{"count":1,"reaction":"PARVOVIRUS B19 INFECTION"},{"count":1,"reaction":"PNEUMONIA"},{"count":1,"reaction":"TINEA INFECTION"},{"count":1,"reaction":"WOUND INFECTION"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Advagraf","FK506MR","MR4"],"phase":"phase_3","status":"active","brandName":"Tacrolimus modified-release","genericName":"Tacrolimus modified-release","companyName":"Hospital de Clinicas de Porto Alegre","companyId":"hospital-de-clinicas-de-porto-alegre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus modified-release works by inhibiting calcineurin, which is involved in the activation of T-lymphocytes. Used for Prevention of organ rejection in kidney transplant patients.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}